Mirion Technologies, Inc. (MIR) Stock Price & How to Invest

Mirion Technologies (NYSE: MIR) designs and sells radiation detection, measurement, analysis and monitoring products across two segments: Nuclear & Safety, which serves nuclear power plants, defense, research labs and industrial customers, and Medical, which supports cancer-care delivery, medical diagnostics and practitioner radiation safety. The company came public through a 2021 SPAC merger and describes itself as the only pure-play public company of its scale in radiation measurement, giving investors combined exposure to the nuclear energy revival and advanced medical applications. Much of its value sits in a large installed base of equipment, dosimetry services and recurring aftermarket revenue.

The investment picture is a growth-and-backlog story running ahead of reported bottom-line profits. Revenue is expanding at a double-digit pace, helped by nuclear power demand and acquisitions such as Paragon and Certrec: second-quarter 2026 revenue was about $267 million, up roughly 20% year over year, and adjusted EPS of $0.12 beat the $0.10 consensus. Trailing revenue now sits just above $1 billion. Even so, the stock has de-rated hard, falling from a 52-week high near $30 to about $15.54 on October 16, 2026, as at least one fund manager noted that backlog is converting into sales more slowly than expected. Mirion carries about $1.23 billion of debt, high interest costs and only about $24.5 million of trailing GAAP net income, so the case rests heavily on adjusted EBITDA, free cash flow conversion and continued order momentum rather than clean accounting earnings.

Mirion has a history of GAAP net losses, and reported earnings remain thin relative to its valuation (a trailing P/E above 170x on about $0.09 of EPS), so much of the story depends on adjusted figures. The balance sheet carries meaningful debt (about $1.23 billion against roughly $425 million of cash) and interest expense, which pressures net income and adds sensitivity to rates. Growth leans on acquisitions, creating integration, goodwill and execution risk. Nuclear project timing can be lumpy and dependent on government funding and utility capital budgets, backlog conversion has run slower than some holders expected, and a large share of revenue ties to a niche end market. The shares have been volatile, down about 35% in 2026 through mid-October even after quarters that beat estimates, and options implied volatility spiked in late September.

11 analysts publish price targets on MIR, averaging $24.00 against a $15.15 price as of October 2026, or +58.4%. The published targets run from $20.00 to $29.00, a moderate spread, and the ratings split 10 buy, 1 hold, 0 sell. Over the last six months there have been 0 raises and 6 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full MIR forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Mirion Technologies, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Nuclear power tailwind. Renewed global interest in nuclear energy, including plant life extensions, new builds and small modular reactors, drives demand for Mirion's detection and safety instrumentation. The most optimistic published target, $29.00, assumes this works close to its best case.

The case against. Mirion has a history of GAAP net losses, and reported earnings remain thin relative to its valuation (a trailing P/E above 170x on about $0.09 of EPS), so much of the story depends on adjusted figures. The most pessimistic target, $20.00, is roughly what MIR is worth if this bites instead.

Read the full bull and bear case on MIR, including what would have to change to break either one. Walnut is not an investment adviser.

No. Mirion Technologies, Inc. (MIR) has not split its stock in the last 10 years. That is a statement about the window we check rather than about the company’s entire history, so an older split is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Mirion Technologies, Inc.'s investor relations page or your broker.

• Revenue (TTM): ~$1.02B
• Revenue (Q2 2026): ~$267M (+~20% YoY)
• Gross / operating margin (TTM): ~48% / ~7%
• Net income (TTM): ~$24.5M
• P/E (trailing / forward): ~173x / ~23x
• 2026 Adj. EBITDA guidance (set early 2026): ~$285M to $300M
• Market cap: ~$3.9B

Mirion trades as a growth-oriented industrial where adjusted EBITDA and free cash flow, not GAAP EPS, anchor most valuation work given thin net income and heavy interest costs. After a roughly 35% fall in 2026 the stock sits near 23 times forward earnings and about 21 times EV to EBITDA, still a premium industrial multiple, while roughly $1.23 billion of debt keeps leverage in focus. Analysts had a mean price target of about $24 in mid-October 2026, well above the share price, and Zacks upgraded the stock to Buy in late September.

Other names that sit close to MIR: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get MIR exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so MIR sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where MIR fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

Mirion is a niche, nuclear-levered radiation-measurement company with revenue growing near 20% and a backlog above $1.1 billion, weighed against thin GAAP earnings, a leveraged balance sheet and a share price that has fallen by about a third in 2026. The October 27, 2026 third-quarter report is the next read on whether backlog is converting into sales fast enough.

Whether MIR is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is MIR a buy or a sell?, and where the stock could go from here in the MIR stock forecast.

For income investors, whether MIR pays a dividend and how the payout looks is covered in does MIR pay a dividend? And to weigh MIR against a peer, read the full side-by-side comparisons: MIR vs TMO and MIR vs AME.